Sign up
Quantellect · Congress · Issuer Profile
NASDAQ: PRAXPraxis Precision Medicines Inc
HealthcareMkt Cap $7.98BCongress ownership rank #3162

Praxis Precision Medicines Inc Congressional Trading

According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 2 trades in Praxis Precision Medicines Inc (NASDAQ: PRAX) since 2026, across 1 member, worth an estimated $16.00K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). Democratic members are responsible for 100% of the trades and Republican members 0%. The most recent disclosure shown was filed October 2026, and Gilbert Cisneros has filed the most PRAX transactions among those shown, with 2. One notable disclosed move was a purchase by Gilbert Cisneros on September 29, 2026, up 8.6% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Praxis Precision Medicines Inc's current Quantellect Tide Score is 56 out of 100 (High Tide), Top 33% of universe (3865); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Praxis Precision Medicines Inc (PRAX) stock overview and the complete trade table below.

Data updated

Trades
2
Politicians
1
Filings
2
Disclosed Vol
$16.00K
Buys
2
100%
Sells
0
0%

Price & congressional trade timeline

Party breakdown

Praxis Precision Medicines congressional trading activity

PoliticianPublishedTradedFiled AfterTypeSizeReturnOwner
Oct 12, 2026Sep 29, 202613 daysBuy
$1,001 - $15,000
+8.61%Self
Sep 4, 2026Jul 30, 202636 daysBuy
$1,001 - $15,000
-0.83%Self
Go to

Praxis Precision Medicines (PRAX) congressional trading FAQ

Can members of Congress legally trade Praxis Precision Medicines (PRAX) stock?

Yes. Members of Congress are permitted to trade individual stocks, including Praxis Precision Medicines (PRAX), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.

Are congressional Praxis Precision Medicines (PRAX) trades public?

Yes. Every congressional trade in Praxis Precision Medicines (PRAX) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.

How many times has Congress traded Praxis Precision Medicines (PRAX)?

Members of Congress have disclosed 2 trades in Praxis Precision Medicines (PRAX) worth $16.00K across 1 members, according to public STOCK Act filings.

Which members of Congress have traded Praxis Precision Medicines (PRAX)?

Recent and active filers of Praxis Precision Medicines (PRAX) disclosures include Gilbert Cisneros. The full member-by-member trade list is on this page.

Do Democrats or Republicans trade Praxis Precision Medicines (PRAX) more?

Across disclosed Praxis Precision Medicines (PRAX) trades, 100% were by Democrats and 0% by Republicans, led by Democrats (100%).

What is the most recent congressional Praxis Precision Medicines (PRAX) trade?

The most recent disclosed Praxis Precision Medicines (PRAX) filing reported a buy by Gilbert Cisneros, filed Oct 11, 2026.

What is Praxis Precision Medicines (PRAX)'s Tide Score?

Praxis Precision Medicines (PRAX) has a Quantellect Tide Score of 56 (High Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.

Browse all stocks Congress tradesCongressional trading overviewPraxis Precision Medicines (PRAX) stock overview

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.